VOR
NASDAQVor Biopharma Inc.
Price$13.17-1.87 (-12.43%)
2026-03-042026-06-05
News · 26 weeks58-86%
2025-12-142026-06-07
Mix3690d
- Other19(53%)
- SEC Filings8(22%)
- Insider7(19%)
- Analyst2(6%)
Latest news
25 items- PRVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 12,900 shares of Vor Bio's common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 202
- PRVor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY. Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation. About Vor BioVor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases.
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
- PRVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineInterim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in The New England Journal of Medicine (NEJM). "We are honore
- SECSEC Form 10-Q filed by Vor Biopharma Inc.10-Q - Vor Biopharma Inc. (0001817229) (Filer)
- PRVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateEnrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary Sjögren's disease Cash and investment balance of $491.5 million as of March 31, 2026 expected to provide runway into early 2029 BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. "We had another quarter of solid execution for our two global Phase 3 programs in
- SECSEC Form EFFECT filed by Vor Biopharma Inc.EFFECT - Vor Biopharma Inc. (0001817229) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Vor Biopharma Inc.SCHEDULE 13G/A - Vor Biopharma Inc. (0001817229) (Subject)
- PRVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 53,400 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 11,350 shares of Vor Bio's common stock to 6 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Induceme
- SECSEC Form S-3 filed by Vor Biopharma Inc.S-3 - Vor Biopharma Inc. (0001817229) (Filer)
- SECSEC Form DEF 14A filed by Vor Biopharma Inc.DEF 14A - Vor Biopharma Inc. (0001817229) (Filer)
- SECSEC Form DEFA14A filed by Vor Biopharma Inc.DEFA14A - Vor Biopharma Inc. (0001817229) (Filer)
- INSIDERDirector Ra Capital Management, L.P. sold $2,604,416 worth of shares (165,150 units at $15.77) (SEC Form 4)4 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sokolove Jeremy Brett3 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
- INSIDERSEC Form 4 filed by Ra Capital Management, L.P.4 - Vor Biopharma Inc. (0001817229) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tcg Crossover Gp Ii, Llc3 - Vor Biopharma Inc. (0001817229) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Vor Biopharma Inc.SCHEDULE 13D/A - Vor Biopharma Inc. (0001817229) (Subject)
VOR FAQ
7 questionsWhat does Vor Biopharma Inc. do?
Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Where does VOR stock trade?
Vor Biopharma Inc. (VOR) is listed on NASDAQ.What sector and industry is VOR in?
Vor Biopharma Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vor Biopharma Inc. go public?
Vor Biopharma Inc. (VOR) completed its IPO in 2021.What are analysts saying about VOR?
Vor Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy on 2026-03-30. Recent price targets range from $900.00 to $4300.00.What companies are similar to VOR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare VOR side-by-side with any of them on Quantisnow.How can I track VOR on Quantisnow?
Quantisnow aggregates Vor Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VOR to receive live email and push alerts on every new disclosure.